Oncternal Therapeutics - Company Profile
Powered by
All the data and insights you need on Oncternal Therapeutics in one report.
- Save hours of research time and resources with
our up-to-date Oncternal Therapeutics Strategy Report
- Understand Oncternal Therapeutics position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Oncternal Therapeutics (Oncternal), formerly GTx Inc, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.
Oncternal Therapeutics premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Cirmtuzumab: |
Chronic Lymphocytic Leukemia (CLL) |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Oncternal Therapeutics | Johnson & Johnson | Pfizer Inc | Gilead Sciences Inc | TG Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | San Diego | New Brunswick | New York | Foster City | Morrisville |
State/Province | California | New Jersey | New York | California | North Carolina |
No. of Employees | 27 | 131,900 | 88,000 | 18,000 | 264 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
David F. Hale | Chairman | Executive Board | 2019 | 74 |
James B. Breitmeyer, M.D., Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2019 | 69 |
Richard G. Vincent | Chief Financial Officer | Senior Management | 2017 | 60 |
Rajesh Krishnan, PhD | Chief Technology Officer | Senior Management | 2020 | - |
Salim Yazji, M.D. | Chief Medical Officer | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward